Antibody Therapeutics Conference 2019

New Generation Immunotherapy: from Discovery to Development 

(CAR-T, ADC, Immuno-Oncology)

Venue:  南港六福萬怡酒店超新星廳 (台北市南港區忠孝東路七段359號7樓)

Time: 2019 / 11 / 7 (四)- 11 / 8 (五)

活動網站:http://walker4.com/atc2019/index.php

>>>報名網址:https://conference.geneonline.news/event/atc2019/


 

       台灣抗體協會將於2019年11月7-8日(星期四下午、星期五全日)於南港六福萬怡酒店超新星廳(台北市南港區忠孝東路七段359號7樓)舉辦「2019 AntibodyTherapeutics ConferenceNew Generation Immunotherapy: from Discovery to Development!」,將聚焦CAR-T, ADC, Immuno-Oncology等領域,邀請海內外學者共同談討,齊聚一堂。

 

        抗體協會自2013年舉辦第一屆ATC論壇,自今已邁入第七個年頭,往年皆吸引超過300人與會。這幾年各國皆如火如荼地投如抗體治療的應用與開發,也有不少成功的進程,台灣當然也不例外,可以感受到產、官、學、研積極投入。除了新標的抗體的開發,如何有效連結產業鏈,成為台灣學研機構共同面臨的課題。我們邀請國內外專家發表專題演講,以期激發跨界討論與合作火花,竭誠邀請各界先進共襄盛舉。

講者簡介:

 Bryan D. Choi, MD, PhD

Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA / Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

 Yu-Hsiang Chang ,MD, Ph.D.

Tai Chen Stem Cell Therapy Center, National Taiwan University Hospital

 Shao Chih Chiu, Ph.D.

Graduate Institute of Biomedical Sciences, China Medical University , Center for Cell Therapy, China Medical University Hospital

 Ming-Tain Lai, Ph.D.

Chief Scientific Officer, OBI Pharma, Inc.

 Simon Shih-Hsien Chuang, Ph.D.

Director, Development Center for Biotechnology,  Medicinal Chemistry Department, Institute of Pharmaceutics

 Keng-Li Lan, M.D., Ph.D.

Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital

 Cheng-I Wang, Ph.D.

Head of the human monoclonal antibody technology platform, Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR)


議程:

11/7 Thursday

Time

Topic and Speaker

13:30-14:00

Registration

14:00-14:10

Opening Remarks

甘良生 理事長 Lawrence Gan, Ph.D
Director of Taiwan Antibody Association; President/CEO, Foresee Pharmaceuticals

紀威光 副執行長 Wei-kuang Chi, Ph.D.
Vice President, Development Center for Biotechnology

14:10-14:15

 

Chimeric Antigen Receptor T Cells (CAR-T)

Moderator:官建村 博士 Chien-Tsun Kuan i, Ph.D.

EVP/ COO & CTO, GenomeFrontier Therapeutics, Inc.

14:15-15:05

Keynote Speaker 

Bryan D. Choi, MD, PhD

Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA / Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

15:05-15:45

CAR-T Cell Therapy for B-cell malignancies

張裕享 醫師 Yu-Hsiang Chang ,MD, Ph.D.

Tai Chen Stem Cell Therapy Center, National Taiwan University Hospital

15:45-16:15

Break

16:15-16:55

Multiple carcinoma targetable CAR for immune cell therapy

邱紹智 博士 Shao Chih Chiu, Ph.D.

Graduate Institute of Biomedical Sciences, China Medical University , Center for Cell Therapy, China Medical University Hospital

16:55-17:00

Closing Remarks

11/8 Friday

Time

Topic and Speaker

9:00-9:15

Registration

9:15-9:20

 

Antibody-drug conjugates (ADC)

Moderator:劉理成 總經理 Lee Cheng Liu, Ph.D.

President/CEO, EirGenix Inc.

9:20-10:10

Keynote Speaker

(邀請中)

10:10-10:50

賴明添 博士 Ming-Tain Lai, Ph.D.

Chief Scientific Officer, OBI Pharma, Inc.

10:50-11:20

Break

11:20-12:00

Site-specific trimannosyl conjugation and ADC capability in DCB

莊士賢 博士 Simon Shih-Hsien Chuang, Ph.D.

Director, Development Center for Biotechnology,  Medicinal Chemistry Department, Institute of Pharmaceutics

12:00-12:05

Closing Remarks

12:05-12:10

Taiwan Antibody Association Members Meeting
公布第三屆理監事當選名單

12:10-14:00

Lunch

14:00-14:05

 

Immuno-Oncology (IO)

Moderator:吳忠勳 執行長 Chung-Hsiun Herbert Wu, Ph.D.

CEO, Development Center for Biotechnology

14:05-14:45

Tumor localized immunotherapy

藍耿立 醫師 Keng-Li Lan, M.D., Ph.D.

Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital

14:45-15:25

(邀請中)

15:25-15:55

Break

15:55-16:45

Keynote Speaker

Engineering cancer immunotherapy

Cheng-I Wang, Ph.D.

Head of the human monoclonal antibody technology platform, Singapore Immunology Network (SIgN),

Agency for Science, Technology and Research (A*STAR)

16:45-16:50

Closing Remarks


主辦單位保留活動變更權力

網路報名費用(請於下方完成報名及繳費):

TAA會員:1500元 / 一般報名:2000元

TAA學生會員:800元 / 一般學生報名:1200元(學生報名需於現場出示學生證明)

※現場報名一律2000元

下列團體會員報名皆享會員價(報名時需提供公司 email 寄送確認信):

中央研究院 / 中天生物科技股份有限公司 / 台康生技股份有限公司 / 台灣醣聯生技醫藥股份有限公司 / 永昕生物醫藥股份有限公司 / 生達化學製藥股份有限公司 / 全福生物科技股份有限公司 / 免疫功坊股份有限公司 / 抗體王生物科技股份有限公司 / 奇異亞洲醫療設備股份有限公司 / 泉盛生物科技股份有限公司 / 財團法人生物技術開發中心 / 國光生物科技股份有限公司 / 基亞生物科技股份有限公司 / 智合精準醫學科技股份有限公司 / 進階生物科技股份有限公司 /圓祥生命科技股份有限公司


主辦單位:

 

連絡電話:台灣抗體協會秘書處 孫先生 (02)77003800 #5216  ericsun@dcb.org.tw